PubRank

Rafael Fonseca

Author PubWeight™ 255.61‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Initial genome sequencing and analysis of multiple myeloma. Nature 2011 17.28
2 Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003 9.96
3 Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007 7.24
4 Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2005 6.98
5 Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007 6.07
6 Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005 5.82
7 Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2009 5.73
8 Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 2010 4.75
9 Clonal competition with alternating dominance in multiple myeloma. Blood 2012 4.39
10 POEMS syndrome: definitions and long-term outcome. Blood 2002 4.35
11 Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003 3.88
12 Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011 3.58
13 Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004 3.43
14 Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005 3.41
15 Association of Clinical Researchers and Educators a statement on relationships between physicians and industry. Endocr Pract 2012 3.27
16 Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011 3.07
17 Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012 2.98
18 Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004 2.97
19 Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006 2.88
20 Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2007 2.87
21 Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009 2.86
22 AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008 2.84
23 Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002 2.63
24 Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004 2.62
25 Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 2013 2.59
26 Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007 2.55
27 Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005 2.54
28 Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009 2.50
29 Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011 2.45
30 Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007 2.34
31 Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res 2007 2.19
32 Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 2009 2.12
33 Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants. Transplantation 2011 2.10
34 Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell 2005 2.01
35 Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004 2.01
36 Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood 2012 1.96
37 Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 2006 1.95
38 Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012 1.91
39 Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012 1.88
40 A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 2005 1.87
41 Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009 1.86
42 Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 2010 1.79
43 Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 2003 1.72
44 Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 2008 1.68
45 Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 2008 1.64
46 Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002 1.57
47 Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res 2009 1.57
48 Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 2003 1.56
49 Waldenström macroglobulinaemia. Lancet Oncol 2003 1.55
50 Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood 2013 1.53
51 Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood 2006 1.50
52 Leukocyte cell-derived chemotaxin 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States. Blood 2014 1.50
53 t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients. Br J Haematol 2003 1.49
54 Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. Haematologica 2005 1.49
55 Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003 1.47
56 Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood 2009 1.44
57 Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005 1.43
58 Impact of providing vitamin A to the routine pulmonary care of extremely low birth weight infants. J Matern Fetal Neonatal Med 2011 1.42
59 DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors. Cancer Res 2010 1.41
60 Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 2002 1.39
61 Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 2002 1.35
62 Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc 2010 1.34
63 Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc 2010 1.32
64 The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood 2007 1.29
65 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet 2006 1.27
66 Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004 1.24
67 Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 2005 1.22
68 Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J Clin Invest 2008 1.22
69 Implementing individualized medicine into the medical practice. Am J Med Genet C Semin Med Genet 2014 1.21
70 Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One 2012 1.21
71 Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood 2008 1.21
72 Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol 2005 1.16
73 Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 2004 1.14
74 Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 2010 1.14
75 Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens. Clin Cancer Res 2011 1.13
76 Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol 2011 1.11
77 Clinical implication of centrosome amplification in plasma cell neoplasm. Blood 2005 1.11
78 Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006 1.11
79 Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol 2010 1.10
80 Plasma cell leukemia. Blood Rev 2011 1.10
81 Smoldering multiple myeloma requiring treatment: time for a new definition? Blood 2013 1.09
82 Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 2012 1.08
83 Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res 2007 1.07
84 Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1. Blood 2011 1.06
85 Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol 2005 1.05
86 Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma. Genes Chromosomes Cancer 2006 1.05
87 Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. Haematologica 2006 1.05
88 Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood 2004 1.05
89 Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood 2002 1.04
90 Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease. Br J Haematol 2014 1.02
91 Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood 2002 1.02
92 Therapeutic options in patients with lymphoma and severe liver dysfunction. Mayo Clin Proc 2004 0.97
93 Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet Cytogenet 2010 0.97
94 Decreased incidence of bronchopulmonary dysplasia after early management changes, including surfactant and nasal continuous positive airway pressure treatment at delivery, lowered oxygen saturation goals, and early amino acid administration: a historical cohort study. Pediatrics 2008 0.96
95 Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood 2002 0.96
96 Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2011 0.95
97 Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility. Cancer Epidemiol Biomarkers Prev 2008 0.94
98 A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. Br J Haematol 2011 0.94
99 Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma. Haematologica 2013 0.93
100 Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. Mod Pathol 2012 0.93
101 Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica 2009 0.93
102 Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction. J Pain Symptom Manage 2012 0.92
103 A novel measure of chromosome instability can account for prognostic difference in multiple myeloma. PLoS One 2013 0.91
104 Review of molecular diagnostics in multiple myeloma. Expert Rev Mol Diagn 2007 0.90
105 Treatment with bortezomib of a patient having hyper IgG4 disease. Clin Lymphoma Myeloma Leuk 2010 0.89
106 A phase II trial of imatinib in patients with refractory/relapsed myeloma. Leuk Lymphoma 2006 0.89
107 Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genet Cytogenet 2002 0.89
108 Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer 2008 0.89
109 Natural history of thromboembolism in AL amyloidosis. Amyloid 2006 0.88
110 An integrated genomic and expression analysis of 7q deletion in splenic marginal zone lymphoma. PLoS One 2012 0.88
111 Comparison of twin and autologous transplants for multiple myeloma. Biol Blood Marrow Transplant 2008 0.87
112 Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia. Br J Haematol 2014 0.87
113 DNA methylation in multiple myeloma is weakly associated with gene transcription. PLoS One 2012 0.87
114 Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood 2012 0.86
115 Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. Br J Haematol 2003 0.85
116 Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications. Blood 2008 0.85
117 Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood 2004 0.85
118 Genetics and cytogenetics of Waldenstrom's macroglobulinemia. Semin Oncol 2003 0.83
119 Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. Br J Haematol 2011 0.83
120 Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. Br J Haematol 2014 0.83
121 Centrosomes and myeloma; aneuploidy and proliferation. Environ Mol Mutagen 2009 0.82
122 t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth. Blood 2012 0.82
123 Dissecting karyotypic patterns in non-hyperdiploid multiple myeloma: an overview on the karyotypic evolution. Clin Lymphoma Myeloma Leuk 2013 0.82
124 [Genetic markers as prognostic factors in multiple myeloma]. Rev Med Chil 2009 0.82
125 Genomics in multiple myeloma: biology and clinical implications. Pharmacogenomics 2005 0.81
126 High-throughput genomic analysis in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011 0.81
127 High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas. Clin Lymphoma Myeloma 2009 0.81
128 A pilot program in collaboration with African American churches successfully increases awareness of the importance of cancer research and participation in cancer translational research studies among African Americans. J Cancer Educ 2012 0.80
129 Genetics of multiple myeloma. Best Pract Res Clin Haematol 2005 0.80
130 Molecular pathogenesis of Waldenstrom's macroglobulinemia. Haematologica 2012 0.78
131 Bone marrow angiogenesis in multiple myeloma: effect of therapy. Br J Haematol 2002 0.78
132 Thrombosis in multiple myeloma (MM). Hematology 2012 0.78
133 Analysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL). J Clin Immunol 2004 0.77
134 Risk stratification of patients with newly diagnosed multiple myeloma: optimizing treatment based on pretreatment characteristics. Clin Lymphoma Myeloma 2005 0.77
135 Genomic abnormalities of Waldenström macroglobulinemia and related low-grade B-cell lymphomas. Clin Lymphoma Myeloma Leuk 2013 0.77
136 Maternal use of cyclobenzaprine (Flexeril) may induce ductal closure and persistent pulmonary hypertension in neonates. J Matern Fetal Neonatal Med 2013 0.76
137 Transfusion-dependent anemia after initiation of androgen deprivation therapy for metastatic prostate cancer. Urology 2007 0.76
138 Genomics and proteomics in multiple myeloma and Waldenström macroglobulinemia. Curr Opin Hematol 2007 0.76
139 Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc 2010 0.75
140 Cell lines of hyperdiploid myeloma, are we there yet? Br J Haematol 2007 0.75
141 Continuing medical education--limiting industry's influence. N Engl J Med 2010 0.75
142 How physicians interpret research funding disclosures. N Engl J Med 2012 0.75
143 In response: the ethics and value of professional medical writing assistance. Endocr Pract 2013 0.75
144 A novel report of cig-FISH and cytogenetics in POEMS syndrome. Am J Hematol 2008 0.75
145 Spontaneous remission in a patient with t(4;14) translocation multiple myeloma. J Clin Oncol 2009 0.75
146 Detection of chromosome 13 deletions by fluorescent in situ hybridization. Methods Mol Med 2005 0.75
147 Acute myocardial infarction: an unusual presentation of essential thrombocytosis in a 17-year-old man. Clin Adv Hematol Oncol 2008 0.75
148 Recurrent chromosome abnormalities define nonoverlapping unique subgroups of tumors in patients with chronic lymphocytic leukemia and known karyotypic abnormalities. Clin Lymphoma Myeloma Leuk 2013 0.75
149 CGH protocols: chronic lymphocytic leukemia. Methods Mol Biol 2013 0.75
150 Unraveling the multiple myeloma genome in the next-generation sequencing era: challenges to translating knowledge into the clinic. Expert Rev Hematol 2011 0.75